JULIA PEÑAS MARTINEZ

Zaragoza-Huesca D, Nieto-Olivares A, Garcia-Molina F, Ricote G, Montenegro S, Sanchez-Canovas M, Garrido-Rodriguez P, Penas-Martinez J, Vicente V, Martinez F, Lozano ML, Carmona-Bayonas A, Martinez-Martinez I. Implication of Hepsin from Primary Tumor in the Prognosis of Colorectal Cancer Patients. Cancers (Basel). 2022 Jun 24;14(13):3106. doi: 10.3390/cancers14133106. PubMed PMID: 35804878; PubMed Central PMCID: PMC9264764.

AÑO: 2022; IF: 6.575

35804878

Rodenas MC, Penas-Martinez J, Pardo-Sanchez I, Zaragoza-Huesca D, Ortega-Sabater C, Pena-Garcia J, Espin S, Ricote G, Montenegro S, Ayala-De La Pena F, Luengo-Gil G, Nieto A, Garcia-Molina F, Vicente V, Bernardi F, Lozano ML, Mulero V, Perez-Sanchez H, Carmona-Bayonas A, Martinez-Martinez I. Venetoclax is a potent hepsin inhibitor that reduces the metastatic and prothrombotic phenotypes of hepsin-expressing colorectal cancer cells. Front Mol Biosci. 2023 May 19;10:1182925. doi: 10.3389/fmolb.2023.1182925. eCollection 2023. PubMed PMID: 37275957; PubMed Central PMCID: PMC10235687.

AÑO: 2023; IF: 5.0

37275957

Zaragoza-Huesca D, Rodenas MC, Penas-Martinez J, Pardo-Sanchez I, Pena-Garcia J, Espin S, Ricote G, Nieto A, Garcia-Molina F, Vicente V, Lozano ML, Carmona-Bayonas A, Mulero V, Perez-Sanchez H, Martinez-Martinez I. Suramin, a drug for the treatment of trypanosomiasis, reduces the prothrombotic and metastatic phenotypes of colorectal cancer cells by inhibiting hepsin. Biomed Pharmacother. 2023 Dec;168:115814. doi: 10.1016/j.biopha.2023.115814. Epub 2023 Oct 31. PubMed PMID: 37918256.

AÑO: 2023; IF: 7.5

37918256